MaxCyte Welcomes Ali Soleymannezhad as Executive Vice President, Pioneering Bioprocessing Advancements

In a strategic move aimed at pushing the boundaries of cell-based therapeutics, MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a trailblazing player in cell engineering, has welcomed Ali Soleymannezhad to their executive team as the Executive Vice President of Bioprocessing. This dynamic addition took effect on August 21, 2023.

Soleymannezhad is set to take the helm in steering global product development and crafting a visionary marketing strategy for MaxCyte’s bioprocessing division. This segment revolves around the game-changing STx and VLx platforms, which empower biotherapeutic research, development, and manufacturing by employing transient expression to scale up the production of intricate proteins, vaccines, and biologics.

Doug Doerfler, President and CEO of MaxCyte, expressed his enthusiasm about the appointment, stating, “With his commercial acumen, strategic prowess, and a proven track record of driving financial excellence, Ali is a formidable addition to our executive leadership. His diverse experience is poised to catapult us beyond the initial success we’ve witnessed with the VLx in our early access program. With Ali’s expertise, we’re primed to deepen our engagement with early access customers and cultivate new partnerships, all while revolutionizing large-scale transfection solutions to tackle the bottlenecks in the ever-evolving cell bioprocessing landscape.”

Ali Soleymannezhad brings nearly two decades of technical brilliance, sales finesse, and marketing mastery in biomanufacturing, bioprocessing, and bioanalysis to his new role. His most recent stint as the Executive Vice President for the Separations and Purification arm at Tosoh Bioscience saw him oversee a global team of 140 professionals across four manufacturing, development, and commercial hubs.

During his tenure at Tosoh, Soleymannezhad donned multiple hats, including Vice President of Global Marketing and Business Development, Director of Sales and Marketing Americas, and served on the board of Semba Biosciences. He holds a Master of Business Administration in finance from the Jones Graduate School of Business at Rice University in Texas, complementing his prior academic achievements—a Master and Bachelor of Chemical Engineering from the University of Western Ontario’s Faculty of Engineering in Canada.

“As someone deeply attuned to the needs and aspirations of life science innovators, one of my key objectives is to forge new frontiers by developing innovative products and services that will further elevate MaxCyte’s stature,” remarked Mr. Soleymannezhad, now the EVP of Bioprocessing. “By executing a compelling marketing strategy aligned with the company’s overarching goals, we’re poised to revolutionize the landscape of cell engineering.” This appointment signals MaxCyte’s unwavering commitment to driving transformative advancements in the realm of cell-based therapeutics.

About MaxCyte 

At MaxCyte, we are on a relentless quest for cell engineering brilliance, driven by a single purpose—to unlock the full potential of cells and revolutionize patients’ lives. With over two decades of unwavering dedication, we’ve honed our craft, crafting cutting-edge platforms, perfecting the intricate art of transfection, and boldly venturing into the realm of tomorrow’s innovations.

Enter the ExPERT™ platform, a marvel born from our Flow Electroporation technology. It stands as a beacon of progress, purpose-built to power the ever-expanding universe of cell therapy. From the inception of groundbreaking discoveries to the development of next-gen cell-based medicines and their triumphant journey to commercialization, ExPERT™ is the unwavering partner every visionary in the high-growth cell therapy sector seeks.

The ExPERT family boasts an impressive lineup, featuring four remarkable instruments: the ATx™, STx™, GTx™, and VLx™. These are complemented by an array of proprietary processing assemblies and disposables, all supported by cutting-edge software protocols. Our global intellectual property portfolio stands as a testament to our commitment to shaping the future of cell engineering.

But we’re not just providers of technology; we’re architects of transformation. Our mission is to empower our partners with the precise tools, unwavering technical support, and the regulatory guidance they need to embark on their odyssey towards reshaping the landscape of human health. Join us on this exhilarating journey to redefine what’s possible in the world of cellular medicine.

Leave a Comment